ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.76
0.31%
US Tech 100
18,318.00
0.95%
S&P 500
5,304.72
0.70%
US Dollar vs CAD
1.36208
-0.07%
Bitcoin
68,765.66
-0.90%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. SciSparc Ltd (SPRC)

  7. SciSparc Ltd (SPRC) News

SPRC

SciSparc (SPRC)

SciSparc Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SPRC
DateTimeSourceHeadlineSymbolCompany
04/11/20247:15AMGlobeNewswire Inc.SciSparc to Acquire AutoMaxNASDAQ:SPRCSciSparc Ltd
03/21/20247:58AMGlobeNewswire Inc.SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer ResearchNASDAQ:SPRCSciSparc Ltd
03/18/20246:29AMGlobeNewswire Inc.SciSparc Granted Another Patent, Strengthening its Core Technology in CanadaNASDAQ:SPRCSciSparc Ltd
03/14/20247:49AMGlobeNewswire Inc.SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical TrialNASDAQ:SPRCSciSparc Ltd
03/12/20247:14AMGlobeNewswire Inc.SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule StructureNASDAQ:SPRCSciSparc Ltd
03/08/20248:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
03/08/20246:11AMGlobeNewswire Inc.SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
03/07/20246:49AMGlobeNewswire Inc.SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in EuropeNASDAQ:SPRCSciSparc Ltd
03/06/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SPRCSciSparc Ltd
03/06/20243:41PMGlobeNewswire Inc.SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management TechnologyNASDAQ:SPRCSciSparc Ltd
02/29/20248:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
02/29/20247:35AMGlobeNewswire Inc.SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of DosingNASDAQ:SPRCSciSparc Ltd
02/27/20243:15PMEdgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:SPRCSciSparc Ltd
02/27/20247:35AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
02/27/20246:58AMGlobeNewswire Inc.SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine CompoundsNASDAQ:SPRCSciSparc Ltd
02/27/20246:58AMGlobeNewswire Inc.Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine CompoundsNASDAQ:SPRCSciSparc Ltd
02/20/20243:27PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
02/20/20246:14AMGlobeNewswire Inc.SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based CompoundsNASDAQ:SPRCSciSparc Ltd
02/20/20246:14AMGlobeNewswire Inc.Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based CompoundsNASDAQ:SPRCSciSparc Ltd
02/12/20243:27PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
01/29/20243:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
01/29/20246:18AMGlobeNewswire Inc.SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum DisorderNASDAQ:SPRCSciSparc Ltd
01/25/20248:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
01/24/20246:42AMGlobeNewswire Inc.SciSparc Ltd. Announces $20 Million Standby Equity Purchase AgreementNASDAQ:SPRCSciSparc Ltd
01/22/20245:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
01/19/20248:28AMGlobeNewswire Inc.SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 millionNASDAQ:SPRCSciSparc Ltd
01/04/20246:18AMGlobeNewswire Inc.SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based TreatmentsNASDAQ:SPRCSciSparc Ltd
01/04/20246:18AMGlobeNewswire Inc.Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based TreatmentsNASDAQ:SPRCSciSparc Ltd
12/13/20237:18AMGlobeNewswire Inc.SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery PlatformNASDAQ:SPRCSciSparc Ltd
12/08/20237:47AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SPRCSciSparc Ltd
 Showing the most relevant articles for your search:NASDAQ:SPRC

Your Recent History

USOTC
MEIVF
Meidensha (PK)
ASX
LLI
Loyal Lithium
LSE
ALTN
Altyngold
ASX
FRN
Fraser Range Metals
ASX
LYKO
Lykos Metals
ASX
TLSKOF
ASX
GAS
State Gas
LSE
0MAU
Exceet
NASDAQ
GGR
Gogoro
ASX
MTBDA
ASX
PVL
Powerhouse Ventures
ASX
RESDA
Resource Generation
ASX
LOTN
Lotus Resources
LSE
0QUT
Episurf Medical Ab
LSE
0ML9
Societatea De Investitii...
ASX
AON
Apollo Minerals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved